Serum thymus and activation‐regulated chemokine as disease activity and response biomarker in alopecia areata
Authors:
- 17 September 2013
- journal article
- research article
- Published by Wiley in The Journal of Dermatology
- Vol. 40 (11) , 881-885
Abstract
Serum thymus and activation‐regulated chemokine/CCL17 (sTARC) is known as a good indicator for atopic dermatitis severity. Herein, we investigate whether sTARC correlates with severity and therapeutic response for alopecia areata (AA) in our 121 patients. The sTARC mean of AA totalis and universalis was significantly higher than mild AA. Next, we compared sTARC of diffuse AA (n = 14) and severity‐controlled patchy AA (n = 32) and found that sTARC in diffuse AA (564.2 ± 400.0 pg/mL) was significantly higher than that of the patchy type (344.0 ± 239.8 pg/mL), suggesting a potential role of TARC in active progression of diffuse AA. Ten patients with diffuse AA were treated with i.v. corticosteroid pulse therapy. Then, we tested whether sTARC can predict prognosis after the pulse therapy and found that baseline sTARC in the poor responders (1025.5 ± 484.8 pg/mL) was significantly higher than that in the good responders (complete remission at 24 months after the pulse therapy, 347.8 ± 135.7 pg/mL), indicating sTARC as a response biomarker in the corticosteroid pulse therapy for diffuse AA. Finally, to investigate TARC production in the affected hair follicles, we performed immunohistochemical double staining of TARC and CD68 using scalp skin specimens of diffuse AA with high titers of sTARC. The results showed their co‐localization in the infiltrating cells around the AA hair follicles, suggesting that TARC is mainly produced from CD68+ histiocytes. In conclusion, sTARC is a disease activity and response biomarker in AA, providing new insight beyond the T‐helper 1/2 paradigm to solve the immunological pathogenesis of AA.Keywords
This publication has 24 references indexed in Scilit:
- CXCL10 produced from hair follicles induces Th1 and Tc1 cell infiltration in the acute phase of alopecia areata followed by sustained Tc1 accumulation in the chronic phaseJournal of Dermatological Science, 2013
- Identification of thymus and activation-regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS)Journal of Dermatological Science, 2013
- Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphomaAmerican Journal of Hematology, 2012
- CCL17/thymus and activation–related chemokine in Churg‐Strauss syndromeArthritis & Rheumatism, 2010
- Serum T helper 1 cytokine levels are greater in patients with alopecia areata regardless of severity or atopyClinical and Experimental Dermatology, 2010
- Impaired responses of peripheral blood mononuclear cells to T-cell stimulants in alopecia areata patients with a poor response to topical immunotherapyBritish Journal of Dermatology, 2008
- Maintenance of Hair Follicle Immune Privilege Is Linked to Prevention of NK Cell AttackJournal of Investigative Dermatology, 2008
- Controlled Delivery of T-box21 Small Interfering RNA Ameliorates Autoimmune Alopecia (Alopecia Areata) in a C3H/HeJ Mouse ModelThe American Journal of Pathology, 2008
- Impaired responses of peripheral blood mononuclear cells to T-cell stimulants in alopecia areata patients with a poor response to topical immunotherapyBritish Journal of Dermatology, 2001
- Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activityJournal of Allergy and Clinical Immunology, 2001